The impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer

Conditions

Topic: Cancer, Surgery

Ghaneh P, Hanson R, Titman A, Lancaster G, Plumpton C, Lloyd-Williams H, Yeo ST, Edwards RT, Johnson C, Abu Hilal M, Higginson AP, Armstrong T, Smith A, Scarsbrook A, McKay C, Carter R, Sutcliffe RP, Bramhall S, Kocher HM, Cunningham D, Pereira SP, Davidson B, Chang D, Khan S, Zealley I, Sarker D, Al Sarireh B, Charnley R, Lobo D, Nicolson M, Halloran C, Raraty M, Sutton R, Vinjamuri S, Evans J, Campbell F, Deeks J, Sanghera B, Wong WL, Neoptolemos JP.

2018-02-0171 citations

10.3310/hta22070

Sample size re-estimation in paired comparative diagnostic accuracy studies with a binary response.

McCray GPJ, Titman AC, Ghaneh P, Lancaster GA.

2017-07-147 citations

10.1186/s12874-017-0386-5

Interventions

Combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnostic work up of patients with suspected pancreatic malignancy

Follow up length: 12 month(s).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with suspected pancreatic malignancy as defined by one or more of: 1.1. Focal lesion in the pancreas/bulky pancreas/dilated pancreatic duct (+/- metastases) detected on Multidetector CT scan (+/- MRI/EUS/USS) 1.2. Jaundice due to distal obstruction of the common bile duct or ampulla (not due to calculi) defined as serum bilirubin. 35 µmol/l 1.3. Serum CA19.9 value above 37KU/l 2. Able to attend for PET/CT scan 3. Able to undergo Multidetector CT scan 4. Able to attend for up to 12 months follow-up 5. Fully informed written consent given 6. Gender: Male & Female 7. Lower Age Limit 18 years

Exclusion criteria

Exclusion criteria: 1. Patients younger than 18 years 2. Pregnancy 3. Patients with poorly controlled diabetes

Design outcomes

Primary

Measure	Time frame
The incremental diagnostic accuracy and impact of PET/CT to standard diagnostic work up; Timepoint(s): Outcome time point will be assessed after 12 Months of follow up	—

Secondary

Measure	Time frame
1. Determine cost effectiveness of addition of PET/CT in diagnosis, staging and management.; Timepoint(s): After 12 months follow up 2. Evaluate addition of PET/CT in differentiating pancreatic malignancy from chronic pancreatitis; Timepoint(s): After 12 months follow up 3. Evaluate change in diagnosis, staging and intended patient management through the addition of PET/CT; Timepoint(s): After 12 months follow up 4. Report the incremental diagnostic value of PET/CT for particular types of pancreatic tumour; Timepoint(s): After 12 months follow up 5. To identify which groups of patients would most benefit from PET/CT; Timepoint(s): After 12 months follow up	—

Measure

Time frame

1. Determine cost effectiveness of addition of PET/CT in diagnosis, staging and management.; Timepoint(s): After 12 months follow up 2. Evaluate addition of PET/CT in differentiating pancreatic malignancy from chronic pancreatitis; Timepoint(s): After 12 months follow up 3. Evaluate change in diagnosis, staging and intended patient management through the addition of PET/CT; Timepoint(s): After 12 months follow up 4. Report the incremental diagnostic value of PET/CT for particular types of pancreatic tumour; Timepoint(s): After 12 months follow up 5. To identify which groups of patients would most benefit from PET/CT; Timepoint(s): After 12 months follow up

—

Countries

United Kingdom

Outcome results

None listed